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The late health effects associated with radioiodine (
131I) given as treatment for thyroid cancer are difficult to assess since the number
of thyroid cancer patients treated at each centre is limited. The risk of second primary malignancies (SPMs) was evaluated in a
European cohort of thyroid cancer patients. A common database was obtained by pooling the 2-year survivors of the three major
Swedish, Italian, and French cohorts of papillary and follicular thyroid cancer patients. A time-dependent analysis using external
comparison was performed. The study concerned 6841 thyroid cancer patients, diagnosed during the period 1934–1995, at a mean
age of 44 years. In all, 17% were treated with external radiotherapy and 62% received
131I. In total, 576 patients were diagnosed with
a SPM. Compared to the general population of each of the three countries, an overall significantly increased risk of SPM of 27% (95%
CI: 15–40) was seen in the European cohort. An increased risk of both solid tumours and leukaemias was found with increasing
cumulative activity of
131I administered, with an excess absolute risk of 14.4 solid cancers and of 0.8 leukaemias per GBq of
131I and
10
5 person-years of follow-up. A relationship was found between
131I administration and occurrence of bone and soft tissue,
colorectal, and salivary gland cancers. These results strongly highlight the necessity to delineate the indications of
131I treatment in
thyroid cancer patients in order to restrict its use to patients in whom clinical benefits are expected.
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Radioiodine (
131I) has been used for over half a century for
diagnostic purposes and for treating patients with hyperthyroid-
ism and papillary or follicular thyroid carcinoma. The radiation
dose delivered by radioiodine to nonthyroidal tissues is relatively
low (International Commission on Radiological Protection (ICRP)
1988) and no increased risk of second primary malignancies
(SPMs) linked to
131I was found in adult patients examined with
131I (Hall et al, 1996) or treated with
131I for hyperthyroidism (Ron
et al, 1998; Franklyn et al, 1999). Much higher activities of
131I are
used to treat thyroid cancer patients, resulting in significant
radiation exposure. However, the late health effects associated with
131I given as treatment for thyroid cancer are difficult to assess
since the number of thyroid cancer patients treated at each centre
is comparatively small. To date, the impact of
131I on the
occurrence of SPM in thyroid cancer patients has been studied
in only three large cohorts (Hall et al, 1991; Dottorini et al, 1995;
de Vathaire et al, 1997). In an effort to obtain a more accurate
quantification of the overall risk of SPM, a pooled analysis of these
three cohorts was performed and follow-up data were extended
beyond the original publications.
The aim of the present study was to evaluate the risk of second
cancer and leukaemia in a cohort of nearly 7000 Swedish, Italian,
and French patients with papillary or follicular thyroid cancer, and
to distinguish any pattern of risk related to exposure to internal
radiation therapy given either alone or in association with external
beam radiation therapy.
PATIENTS AND METHODS
Patients
A common database was obtained by pooling patients with
papillary or follicular thyroid cancer of three major European
cohorts. Patients with a malignancy prior to thyroid cancer, with a
second malignancy within the first 2 years of follow-up, or dying
within 2 years of diagnosis were excluded. The treatment
modalities in each cohort have been described previously (Hall
et al, 1991; Dottorini et al, 1995; de Vathaire et al, 1997).
The Swedish cohort consisted of patients initially treated
between 1951 and 1977 at the Departments of Oncology of the
six university hospitals in Sweden (Hall et al, 1991). The Italian
cohort included patients initially treated between 1958 and 1995 in
the Nuclear Medicine Department of the General Hospital in Busto
Arsizio (Dottorini et al, 1995). The French cohort included patients
initially treated between 1934 and 1995 in the Cancer Centres of
Villejuif, Reims, and Caen (de Vathaire et al, 1997).
The end point of the study was fixed at 31 December 1997 and
not later because, in the absence of recurrent disease, medical
surveillance became less frequent after the first 5 years of follow-
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lThe follow-up of patients of the Swedish cohort was updated
through the Swedish Cancer Registry, and the follow-up of patients
of the other two cohorts was updated through the medical records
of each institution. Additionally, for each
131I administration, the
date and activity were recorded in order to perform a time-
dependent analysis (see Statistical analysis).
Compared to the previous reports, the Swedish cohort
concerned the same patients but with a mean follow-up extended
for 5 years. In the Italian cohort, patients initially treated between
1991 and 1995 were also included, as well as patients followed for
less than 3 years who were previously excluded; patients who
received external radiotherapy at the time of initial treatment were
excluded, because technical parameters needed for dose calcula-
tion could not be obtained. In the French cohort, patients initially
treated between 1992 and 1995 and patients initially treated by
external radiotherapy were also included.
Statistical analysis
A time-dependent analysis using external comparison was
performed. Patients were considered at risk for second cancer
during the period of time beginning 2 years after thyroid cancer
diagnosis until any of the following four events: (1) 31 December
1997; (2) occurrence of an SPM; (3) death; (4) last visit to the
‘Cancer Centre’. Additionally, the occurrence of a third malignancy
was considered in the site-by-site analysis only if it occurred
during the first 2 years after a second malignant neoplasm.
Malignancies that occurred later were excluded from the analysis
since it was not possible to separate the effects of the thyroid
cancer and SPM treatments.
Histological diagnosis was obtained for all second primaries and
this allowed to exclude the possibility of metastases, especially in
the lungs, bones, and brain.
The expected numbers of SPM were calculated by multiplying
the gender, age, and calendar-year-specific person-years at risk
with the corresponding incidence rates in each country. The data
of the Swedish Cancer Registry (Cancer Incidence in Sweden, 2000)
were used as reference rates for the Swedish cohort. Data of the
registry of Varese, Lombardy, were used as reference rates for the
patients included in the Italian cohort (Muir et al, 1987; Parkin
et al, 1992, 1997) and for the 229 patients of the French cohort who
came from Italy. The reference rates for the French patients were
estimations of cancer incidences in France during the period
1975–1995 (Menegoz and Cherie ´-Challine, 2000). For sites not
included in this estimation, two other data sets were used, covering
the periods 1978–1982 (Benhamou et al, 1990) and 1983–1987 (de
Vathaire et al, 1996). As no incidence rate was available before
1958 for Sweden, before 1976 for Italy, and before 1975 for France,
the expected numbers of malignancies before these dates were
calculated with the incidence rates of the following nearest period
of time for each country. This approximation concerned only 6%
of the follow-up.
The observed number of cancers was assumed to follow a
Poisson distribution (Breslow and Day, 1987) and standardised
incidence ratios (SIRs) were calculated as the ratio of observed to
expected numbers. As age, gender, and calendar period were taken
into account in the calculation of the expected numbers, the
modelling of the SIRs was stratified only on country.
The exposure to external radiotherapy was considered as a
binary variable. All
131I treatment courses administered up to 2
years before the end of the follow-up were taken into account. The
131I activity administered was analysed as a time-dependent
variable: a patient, at a given time, was considered to be exposed
to a risk of SPM related only to the cumulative activity
administered previously. In this time-dependent analysis, the risk
of SPM at a given calendar period, gender, and attained age was
modelled as a function of the expected number of SPMs from the
reference rates, and of the cumulative
131I activity administered 2
years or more before.
In order to estimate the risk of SPM per administered activity,
excess relative risk (ERR) per GBq and excess absolute risk (EAR)
per GBq and 100000 person-years of follow-up were modelled as a
linear function of the cumulative activity of
131I administered 2
years or more before. Radioiodine activity was also treated as a
categorised variable, reflecting 1–4 standard treatments of
3.7GBq. This could not be done for leukaemias due to insufficient
numbers.
The significance of the parameters was tested by comparing the
module of EPICURE deviance of nested models. The analysis was
done by using AMFIT software (Preston et al, 1991). Confidence
intervals (95% CI) of the risk were estimated using maximum
likelihood methods (Moolgavkar and Venzon, 1987). When
convergence was not obtained and lower or upper bounds not
estimable with this technique, a question mark was reported in the
results. All analyses of the pooled cohort were stratified on the
study groups and heterogeneity between study groups was sought.
RESULTS
The study concerned 6841 thyroid cancer patients diagnosed
during the period 1934 and 1995 (Table 1). About 20% of them
were lost to follow-up. An approximate 3:1, female to male ratio
was seen and the mean age at diagnosis was 44 years. In all, 17%
were treated with external radiotherapy and 62% received
131I.
Only 9% received both external radiotherapy and
131I. The mean
follow-up period after thyroid cancer diagnosis was 13 years
(range: 2–55 years) (Table 1). The mean interval of time between
thyroid cancer diagnosis and SPM was 15 years (range: 2–55
years), and the mean age at SPM diagnosis was 64 years (range:
21–99 years; data not shown).
Table 1 Characteristics of the patients treated for a papillary or a follicular thyroid cancer of the three cohorts and of the pooled cohort
Swedish cohort Italian cohort French cohort Pooled cohort
Patients
Number 1894 1894 3053 6841
Treatment period (years) 1951–1977 1958–1995 1934–1995 1934–1995
Males (%) 460 (24) 433 (23) 688 (23) 1581 (23)
Mean age at thyroid cancer diagnosis (range) 49 (5–91) 44 (5–82) 42 (2–91) 44 (2–91)
Mean follow-up duration (years) 20 (2–46) 8 (2–35) 12 (2–55) 13 (2–55)
Treatment
Thyroid surgery (%) 1783 (94) 1891 (100) 3002 (98) 6676 (98)
External beam radiotherapy (%) 725 (38) 17 (1) 452 (15) 1194 (17)
Treatment with
131I (%) 795 (42) 1576 (83) 1854 (61) 4225 (62)
Mean cumulative
131I activity in GBq
a (range) 3.8 (0.4–49.2) 5.9 (0.9–34.4) 6.9 (0.2–55.5) 6.0 (0.2–55.5)
aIn case of treatment with
131I, cumulative activity administered up to 2 years before the end of follow-up or the diagnosis of second primary malignancies is measured.
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lIn total, 576 patients were diagnosed with an SPM, among whom
13 developed a third malignant neoplasm less than 2 years after the
SPM. For all the 6841 thyroid cancer patients, an overall
significantly increased risk of cancer of 27% (95% CI: 15–40)
compared to the general population of each of the three countries
was seen and the risk did not differ between men and women (data
not shown). Significantly increased risk of cancer in the digestive
tract (SIR¼1.2, n¼126), bone and soft tissue (SIR¼5.9, n¼19),
skin melanoma (SIR¼2.3, n¼25), kidney (SIR¼2.6, n¼31),
central nervous system (SIR¼2.1, n¼21), endocrine glands other
than thyroid (SIR¼3.6, n¼18), and leukaemias (SIR¼1.8,
n¼18) was seen for the 6841 patients. No significant gender
difference was seen (data not shown). Furthermore, a significantly
increased risk was seen for female breast cancer (SIR¼1.3,
n¼128) and for genital male cancers (SIR¼1.5, n¼30).
No significant association was found between exposure to
external radiotherapy and risk of SPM, except for bone and soft-
tissue cancers (RR¼2.9, 95% CI: 1.2–7.3). Furthermore, no
interaction was evidenced between external radiotherapy and
131I
administration for the risk of SPM.
The risk of SPM occurrence in relation to
131I administration is
described in Table 2. When contrasting those exposed and not
exposed to
131I, after stratifying for study cohort and adjusting for
external radiotherapy, increased relative risks were seen for the
bone and soft tissue (RR¼4.0), female genital organs (RR¼2.2),
central nervous system (RR¼2.2), and leukaemia (RR¼2.5)
(Table 2). Of the 13 cancers of oral cavity, seven were cancers of
the salivary glands: six of them occurred in patients treated with
131I( n¼4225), and only one in patients treated by other means
(n¼2616). SIR was not calculated for salivary gland cancer since
French reference rates are lacking for this localisation but analysis
using internal comparison yielded a relative risk of 7.5 (95% CI:
1.2–143).
Among the 344 patients aged less than 20 years at thyroid cancer
diagnosis, 13 SMNs occurred, including two digestive tract, one
lung, two bone, five breast, two endocrine cancers, and one
malignant lymphoma. Compared to the general population, the
overall risk of SPM was significantly increased (SIR¼2.5), as well
as the risk of secondary breast cancer (SIR¼3.4). In all, 61% of the
young patients were treated by
131I and no carcinogenic effect of
131I was found (RR¼1.1).
An increased risk of both solid tumours and leukaemias was
seen with increasing cumulative activity of
131I administered after
adjustment for external radiotherapy (Table 3). A linear relation-
ship without any significant quadratic effect best fitted the
description of the solid tumours (w
2¼0.46, P¼0.5). An ERR of
3.5 % (95% CI: 0.9–6.9%) per GBq of
131I was seen. The ERR was
similar for patients who did or did not receive external radio-
therapy, being 3.4% (95% CI: 0.2–7.8%) and 3.5% (95% CI: 0.01–
8.6%), respectively (Table 4). An EAR of 14.4 solid cancers per GBq
of
131I administered and per 10
5 person-years of follow-up was
estimated. No heterogeneity of the results was found between
cohorts (P¼0.7). An even stronger relationship was found
between the cumulative activity of
131I administered and the risk
of leukaemia (Tables 3 and 4). The relationship was linear, without
any significant quadratic effect (w
2¼0.2, P¼0.7). The ERR for
leukaemia was 39% (95% CI: ?–154%) per GBq and the EAR was
estimated to be 0.8 cases per GBq of
131I administered and per 10
5
person-years of follow-up. External radiotherapy, treated as a
binary variable (exposed vs nonexposed), did not influence
Table 2 Observed number of SPMs, standardized incidence ratio (95% confidence interval) and risk of SPM in relation to
131I administration, among the
6841 patients treated for a papillary or follicular thyroid cancer
All the patients (PYR¼77955)
131I therapy (PYR¼37702) No
131I therapy (PYR¼40253)
Cancer site (ICD9 code)
Number
of SPMs SIR
a (95% CI)
Number of
SPMs SIR
a (95% CI)
Number
of SPMs SIR
a (95% CI)
Relative
risk
b:
131I vs no
131I
(95% CI)
Oral cavity (140–145) 13 2.0 (1.0–3.4) 10 2.6 (1.2–4.8) 3 0.8 (0.2–2.2) 2.8 (0.8–13.0)
Salivary glands (142)
c 7 – 6 – 1 – 7.5 (1.2–143)
Pharynx (146–149) 3 0.5 (0.09–1.6) 1 0.3 (0.02–1.5) 2 0.9 (0.2–2.9) 0.4 (0.02–4.7)
Digestive tract (150–159) 126 1.3 (1.0–1.5) 61 1.2 (0.9–1.5) 65 1.4 (1.0–1.8) 1.1 (0.8–1.5)
Stomach (151) 20 1.1 (0.6–1.7) 10 1.0 (0.5–1.7) 10 1.0 (0.5–1.7) 1.3 (0.5–3.2)
Colon and rectum (153–154) 69 1.3 (0.9–1.6) 37 1.4 (0.9–1.9) 32 1.1 (0.7–1.7) 1.3 (0.8–2.0)
Respiratory organs (161–163) 37 0.9 (0.6–1.3) 20 1.0 (0.6–1.6) 17 0.8 (0.4–1.4) 1.1 (0.5–2.3)
Lung cancer (162) 32 1.0 (0.6–1.4) 18 1.0 (0.6–1.6) 14 0.9 (0.4–1.7) 1.1 (0.5–2.3)
Bone and soft tissue (170–171) 19 5.9 (3.6–9.0) 14 5.8 (2.5–11.2) 5 1.8 (0.3–5.5) 4.0 (1.5–12.4)
Skin melanoma (172) 25 2.5 (1.6–3.7) 11 2.1 (1.1–3.8) 14 2.9 (1.6–4.9) 0.8 (0.3–1.8)
Breast (174) 128 1.3 (1.0–1.5) 54 1.2 (0.9–1.6) 74 1.3 (1.0–1.7) 0.8 (0.5–1.1)
Female genital organs (179–183) 57 0.7 (0.5–1.0) 36 0.9 (0.6–1.3) 21 0.6 (0.3–0.9) 2.2 (1.3–3.9)
Uterus (179–182) 39 1.0 (0.7–1.4) 25 1.1 (0.7–1.7) 14 0.8 (0.4–1.4) 2.3 (1.2–4.7)
Ovary (183) 20 0.5 (0.3–0.8) 12 0.7 (0.3–1.2) 8 0.4 (0.1–0.8) 2.0 (0.8–5.2)
Male genital organs (185–186) 30 1.6 (1.0–2.4) 16 1.3 (0.6–2.3) 14 2.0 (1.1–3.4) 1.1 (0.5–2.3)
Urinary tract (188–189) 50 1.8 (1.3–2.4) 31 2.1 (1.4–3.1) 19 1.4 (0.7–2.3) 1.5 (0.9–2.8)
Bladder (188) 19 1.2 (0.7–1.9) 12 1.4 (0.7–2.3) 7 0.4 (0.1–1.2) 1.6 (0.6–4.5)
Kidney (189) 31 2.6 (1.7–3.8) 19 2.6 (1.5–4.4) 12 2.6 (1.3–4.5) 1.5 (0.7–3.3)
Central nervous system (191–192) 21 2.5 (1.5–3.8) 13 3.0 (1.6–5.2) 8 1.9 (0.8–3.7) 2.2 (0.9–5.7)
Endocrine glands (194) 18 3.1 (1.6–5.3) 10 5.2 (2.4–9.7) 8 1.5 (0.4–1.4) 1.6 (0.6–4.3)
Lymphoma (200–202) 17 1.1 (0.6–1.8) 10 1.1 (0.5–2.2) 8 1.2 (0.5–2.5) 1.0 (0.4–2.8)
Multiple myeloma (203) 6 1.4 (0.5–2.9) 4 1.6 (0.5–3.6) 2 0.6 (0.03–2.6) 1.4 (0.3–0.7)
Leukaemia (204–208)
d 18 1.6 (0.8–2.7) 12 1.9 (0.8–3.6) 6 1.2 (0.4–2.8) 2.5 (1.0–7.4)
Other
e 21 0.9 (0.5–1.5) 8 0.6 (0.2–1.3) 13 1.2 (0.6–2.1) 0.6 (0.2–1.5)
At least one cancer
f 576 1.3 (1.2–1.4) 301 1.3 (1.1–1.5) 275 1.3 (1.1–1.4) 1.2 (1.0–1.4)
PYR¼Number of person-years of follow-up.
aStandardised incidence ratio adjusted on external radiotherapy.
bRelative risk stratified on study group and adjusted on external
radiotherapy.
cNo SIR could be calculated for this cancer since French reference rates are lacking for this localization.
dOne woman developed a leukaemia less than 1 year after
the occurrence of a breast cancer.
eIncluding the following sites (ICD9 code): 160, 164, 165, 175, 184, 187, 190, 195–199.
fNumber of patients with at least one cancer excluding
thyroid cancers and nonmelanoma skin cancers: 13 patients with two second malignancies within 2 years.
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lsignificantly the relationship between the amount of
131I adminis-
tered and the risk of leukaemia.
A significant dose–effect relationship was found for bone and
soft-tissue cancers and for colorectal cancers after adjustment for
external radiotherapy (Tables 4 and 5), the ERR per GBq of
131I
administered being 61% (95% CI: ?–241%, Po0.01) and 10% (95%
CI: 1–27%, P¼0.03), respectively, with no evidence for an
interaction between
131I administration and external radiotherapy.
A significant relationship was found between the risk of female
genital cancer and the amount of
131I administered, although there
was no significant increase in the overall SIR. For cancer of the
central nervous system, a nearly significant increase of the ERR
with the amount of
131I administered was found (P¼0.13).
The ERR for solid tumours did not vary widely with time after
exposure to
131I: among the 3211 patients followed at least 10 years
after thyroid cancer treatment, the ERR of SPM more than 10 years
after the last
131I treatment was 6% (95% CI: 1–12%) per GBq of
131I administered.
DISCUSSION
We found a significant 30% increased risk of developing a SPM in
one of the largest cohorts of thyroid cancer patients reported to
date. A linear dose–response relationship with
131I administration
was seen for all cancers combined and for leukaemia, and we
estimated that a treatment of 3.7GBq of
131I will induce an excess
of 53 solid malignant tumours and 3 leukaemias, in 10000 patients
during 10 years of follow-up. In addition, we identified a strong
relationship between the cumulative activity of
131I and risk of
bone and soft-tissue cancer, colorectal cancer, and salivary gland
cancer. The increased incidence of SPM seen in the present study
and previously reported (Tucker et al, 1985; Hall et al, 1990, 1991;
Dottorini et al, 1995; Edhemovic et al, 1998) could also be related
to an increased medical surveillance, common aetiological factors
including hereditary factors, or misclassified metastases. Although
increased medical surveillance could contribute to an earlier
detection of cancers with a long latency, it could hardly explain the
excess of leukaemia and of solid cancers with a poor prognosis and
a rapid evolution.
Ionising radiation is the only established cause of thyroid cancer
in humans (UNSCEAR, 2000). Other risk factors, such as diet,
reproductive factors, deficiency or excess of iodine, changes in
height and weight, have been involved in some studies (La Vecchia
et al, 1999; Negri et al, 1999; Dal Maso et al, 2000; Horn-Ross et al,
2001). It is not likely that any of these factors would profoundly
influence the risk related to radioiodine since we found a
difference between exposed and nonexposed tumours, and, for
some tumours, a dose–response relationship. Some rare familial
syndromes associated with an excess risk of thyroid cancer include
familial adenomatous polyposis, Carney complex, and Cowden
syndrome (Stratakis et al, 1997; Lindor and Greene, 1998). Owing
to their rarity, these syndromes probably did not influence our risk
estimates.
In all, 20% of patients were lost to follow-up before 1997 as a
result of the routine long-term follow-up programmes. This has
probably not introduced any bias in the study, because the
frequency of patients who lost to follow-up was quite similar
among patients who did or did not receive
131I treatment.
Moreover, if the end point of the study is fixed at 31 December
Table 3 Risk of SPMs as a function of the cumulative
131I activity administered 2 years or more before the diagnosis of SPM
No external radiotherapy External radiotherapy All patients
Type of SPM
Amount of
131I (GBq)
Number of
SPM/PYR
RR
a
(95% CI)
Number of
SPM/PYR
RR
a
(95% CI)
Number of
SPM/PYR
RR
b
(95% CI)
Solid cancers
c p0.2 186/29625 1 (ref) 84/10629 1 (ref) 270/40254 1 (ref)
[0.2–3.6] 98/10795 1.2 (0.9–1.5) 23/2553 1.1 (0.7–1.7) 121/13348 1.2 (0.9–1.4)
[3.7–7.3] 78/14330 0.9 (0.7–1.2) 24/2178 1.4 (0.9–2.3) 102/16508 1.0 (0.8–1.3)
[7.4–14.7] 32/4693 1.4 (1.0–2.1) 12/1184 1.6 (0.9–3.0) 47/5877 1.5 (1.0–2.0)
X14.8 12/1475 1.5 (0.8–2.6) 7/495 2.1 (0.9–4.7) 19/1970 1.6 (1.0–2.6)
Leukaemias p0.2 4/29625 1 (ref) 2/10629 1 (ref) 6/40254 1 (ref)
[0.2–3.6] 3/10795 1.4 (0.3–6.6) 1/2553 2.2 (0.1–23.5) 4/13348 1.8 (0.4–6.3)
[3.7–18.4] 4/19644 2.6 (0.5–11.8) 3/3485 4.3 (0.7–34.9) 7/23129 3.1 (1.0–10.3)
X18.5 0/853 – 1/372 14.0 (0.6–167.4) 1/1225 7.5 (0.4–48.7)
PYR¼Number of person-years of follow-up.
aRelative risks stratified on study group.
bRelative risks adjusted on external radiotherapy and stratified on study group.
cAll cancers
excluding leukaemias, thyroid cancers, and nonmelanoma skin cancers.
Table 4 Excess of relative risk per cumulative activity of
131I in GBq (ERR) according to external radiotherapy for major types of SPMs
No external radiotherapy External radiotherapy All the patients
Type of SPM
ERR per
GBq of
131I
a
(95% CI)
Test of
trend
b
ERR per
GBq of
131I
a
(95% CI)
Test of
trend
b
ERR per
GBq of
131I
c
(95% CI)
Test of
trend
b
Test of
heterogeneity
d
Solid cancers
e 0.03 (0.002–0.08) 0.03 0.04 (0.00006–0.09) 0.05 0.04 (0.009–0.07) o0.01 0.6
Soft-tissue and bone cancer 0.29 (?–1.74)
f 0.2 1.04 (?–3.93)
f o0.001 0.61 (?–2.41)
f o0.001 0.9
Colorectal cancer 0.15 (0.02–0.38) 0.01 0.02 (?–0.20)
f 0.7 0.10 (0.08–0.27) 0.03 0.4
Breast cancer 0.002 (?–0.07)
f 1.0  0.02 (?–0.04)
f 0.3  0.01 (?–0.04)
f 0.6 0.3
Leukaemias 0.22 (?–1.30)
f 0.2 0.59 (?–2.34)
f o0.01 0.39 (?–1.54)
f 0.01 0.4
aStratified on study group.
bTest of trend for a linear dose–effect relationship: P-value.
cAdjusted on external radiotherapy and stratified on study group.
dTest of heterogeneity of
the ERR between patients exposed and nonexposed to external radiotherapy.
eAll cancers except leukaemias, thyroid cancers, and nonmelanoma skin cancers.
fLower bound
not calculable.
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3.3% per GBq of
131I (95% CI: 0.2–7.5%), whereas about 10% of
patients are lost to follow-up.
All efforts were made to increase the specificity of SPM through
exclusion of distant metastases particularly in the lungs,
bones, and brain. When excluding the sites where possible
misclassification of SPM could occur, the overall risk of SPM
remained significantly increased in the
131I exposed group
(P¼0.02).
Despite the known carcinogenic effect of ionising radiation, no
association was evidenced between external radiotherapy and SPM
occurrence in our study except for soft and bone cancers, and no
interaction was found between external radiotherapy and
131I
administration. This could result from the small number of
patients treated by external radiotherapy: less than 1/5 of the
patients were treated by external radiotherapy and less than 1/10
received external radiotherapy and
131I.
All the analyses were nevertheless adjusted on external radio-
therapy in an attempt to access the own effect of
131I on SPM
occurrence.
The increased risk of leukaemia was previously observed in the
Swedish cohort, but not in the Italian and French cohorts,
demonstrating the advantage of a pooled analysis. The dose–
response relationship was clearly linear, and most cases of
leukaemia occurred in patients treated with high cumulative
activities of
131I. We also evidenced a significant relationship
between the cumulative activity of
131I administered and the risk of
solid cancer, with an excess of 4% per GBq. This major result was
already suggested in each of the three cohorts included in our
pooled analysis.
Significantly increased risks with higher cumulative amount of
131I was only seen for colorectal cancer, bone and soft-tissue
cancer, and salivary gland cancer. The excess of colorectal cancer
was previously evidenced only in the French cohort (de Vathaire
et al, 1997), and the excess of salivary gland cancer was found in
the Swedish (Hall et al, 1991) and Italian (Dottorini et al, 1995)
cohorts. In contrast, the excess of bone and soft-tissue cancers
following
131I administration has not been previously reported. In
fact, an excess of these cancers could only be shown in large
cohorts, because they are infrequent in the general population.
These cancers have been frequently associated to local high doses
of radiation delivered by external radiotherapy (UNSCEAR, 2000);
indeed, we found that they were associated with exposure to
external radiotherapy. However, the increasing risk of soft tissue
and bone cancer with a higher cumulative amount of
131I remained
significant after adjustment on exposure to external radiation
therapy. Finally, the dose–response relationship seen in our series
may be due to the use of larger activities of
131I in patients with
bone metastases, and in these patients a dedifferentiation of
metastatic lesions may occur and can rarely be totally separated
from a SPM. However, the rarity of this event argues against its
large influence on our risk estimate.
Ionising radiation can induce tumours of the central nervous
system, although the relationship is weaker than for many other
tumours, and most radiation-associated tumours are benign
(UNSCEAR, 2000). The increased risk of central nervous system
cancers in our study leads to question about the radiation doses
delivered to the brain after repeated
131I administrations for
thyroid cancer.
An increased incidence of breast cancer was found among
women treated for thyroid cancer as compared to the general
population; however, this was not related to
131I exposure, even
among the women who were less than 40 years old at the time of
thyroid cancer diagnosis. This confirms that the radiation dose to
the mammary tissue is low following
131I treatment, despite the
expression of the sodium iodide symporter in some physiological
or pathological conditions (Tazebay et al, 2000); in fact, the
mammary tissue is rarely visualised on
131I total body scanning
(Hammami and Bakheet, 1996). This finding is in accordance with
a case–control study nested in the Swedish cohort (Hall et al,
1992) and may be related to a closer medical surveillance or to
common aetiological factors. In fact, some population-based
cohort studies indicate an increase of thyroid cancer after breast
cancer treatment and an increase of breast cancer after thyroid
cancer (Ron et al, 1984; Teppo et al, 1985; Li et al, 2000). However,
other studies only identified an increased risk of breast cancer
after thyroid cancer treatment (Vassilopoulou-Sellin et al, 1999;
Chen et al, 2001).
Similarly, an increased incidence of kidney cancer was found
but was not related to
131I exposure. This is in accordance with a
previous case–control study nested in the Swedish cohort, and is
not surprising as kidney cancer is not described as a frequently
radiation-induced cancer (UNSCEAR, 2000). All population-based
cohort studies of patients treated for thyroid cancer reported an
increased incidence of kidney cancer (Osterlind et al, 1985; Tucker
et al, 1985; Shikhani et al, 1986; Akslen and Glattre, 1992; Ishikawa
et al, 1996; Edhemovic et al, 1998), which may be related to
common etiological factors.
For each activity of
131I administered, the organ doses delivered by
131I to thyroid cancer patients are higher than in euthyroid subjects
due to a decreased renal clearance and prolonged body retention of
131I caused by the hypothyroid condition (M’Kacher et al,1 9 9 6 ) .D u e
to the local accumulation of
131I, the stomach, salivary glands, and
bladder receive the highest radiation doses. In hypothyroid patients,
131I is also accumulated in the colon lumen due to a decreased
colonic motility. The risk of colorectal and salivary gland cancers
should be minimised by a simple routine of having patients drink
large quantities of fluids and lemon juice, and by the use of laxatives.
Despite the known accumulation of
131I in the stomach and bladder,
we did not find any increased risk for these sites.
Our results concern high activities of
131I and do not apply to the
general population or to patients treated with
131I for hyperthyr-
oidism, since the accumulation of
131I is low or absent in the colon
lumen of euthyroid or hyperthyroid patients.
Table 5 Relative risk of soft-tissue and bone cancer, colorectal cancer, and breast cancer as a function of the cumulative
131I activity administered 2 years
or more before the diagnosis of SPMs
Number of SPMs and RR
a (95% CI)
Amount of
131I (GBq) Soft-tissue and bone cancer Colorectal cancer Breast cancer
p0.2 5 1 (ref) 32 1 (ref) 74 1 (ref)
[0.2–3.6] 5 2.9 (0.8–10.7) 12 0.9 (0.5–1.8) 23 0.9 (0.5–1.4)
[3.7–7.3] 4 3.4 (0.8–13.3) 13 1.1 (0.6–2.2) 19 0.6 (0.3–1.0)
[7.4–14.7] 3 7.7 (1.5–33.3) 8 2.5 (1.0–5.5) 9 1.0 (0.4–1.9)
X14.8 2 13.0 (1.7–67.1) 4 3.2 (0.9–8.7) 3 0.9 (0.2–2.5)
aRelative risk adjusted on external radiotherapy and stratified on study group.
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lIn conclusion, we report an excess of 53 cases of solid
malignancy and of three cases of leukaemia per 10 years among
10000 patients treated with a standard activity of 3.7GBq of
131I.
Indeed, these results do not contraindicate the therapeutic use of
131I in patients for whom a clinical benefit is expected. However, as
the dose–response relationships for
131I administration were
linear, it seems necessary to restrict the repeated use of
131It o
thyroid cancer patients in whom it may be beneficial (Schlumber-
ger, 1998).
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